Ticker Details
Halozyme Therapeutics, Inc. Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
IPO Date:	March 16, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$12.28B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 2.39%
Avg Daily Range (30 D):	$1.89 | 2.14%
Avg Daily Range (90 D):	$1.44 | 1.87%

Institutional Daily Volume
Avg Daily Volume:	.99M
Avg Daily Volume (30 D):	1.8M
Avg Daily Volume (90 D):	1.53M

Trade Size
Avg Trade Size (Sh.):	100
Avg Trade Size (Sh.) (30 D):	62
Avg Trade Size (Sh.) (90 D):	57

Institutional Trades
Total Institutional Trades:	11,312
Avg Institutional Trade:	$3.31M
Avg Institutional Trade (30 D):	$6.81M
Avg Institutional Trade (90 D):	$6.03M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.79M
Avg Closing Trade (30 D):	$21.44M
Avg Closing Trade (90 D):	$21.57M
Avg Closing Volume:	169.55K

News

Jun 22, 2026 @ 12:00 PM LifeMD Announces Exclusive Collaboration to Launch... Source: Lifemd, Inc.

May 5, 2026 @ 8:00 PM Acumen Pharmaceuticals to Report First Quarter Fin... Source: Na

Mar 19, 2026 @ 8:00 PM Acumen Pharmaceuticals to Report Fourth Quarter an... Source: Na

Mar 10, 2026 @ 8:00 PM Acumen Pharmaceuticals to Participate in the Stife... Source: Na

Jan 28, 2026 @ 6:58 PM Halozyme Therapeutics Projects Sustained Growth We... Source: Vandana Singh

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$3.56	$1.96	$1.27
Diluted EPS	$3.42	$1.9	$1.22
Revenue	$1.66B	$481M	$376.71M
Gross Profit	$1.37B	$401.83M	$297.47M
Net Income / Loss	$413.6M	$229.91M	$150.05M
Operating Income / Loss	$597.2M	$287.65M	$184.52M
Cost of Revenue	$292.42M	$79.17M	$79.24M
Net Cash Flow	$102.13M	$-148.02M	$175.59M
PE Ratio